Tom Powles: Truqap Combination Improves RPFS in PTEN-Deficient Prostate Cancer
Tom Powles, Director of Barts Cancer Centre, shared a post on X:
“Positive PFS results for the AKT inhibitor capivasertib in hormone sensitive PTEN defficent prostate cancer (with Abi and ADT). A trend towards OS (immature) described. Chemotherapy triplets are also used in high volume disease.”
More posts featuring Tom Powles.
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre.
With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
Further Reading:
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023